- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Pwynt Penodol mewn Amser (31/12/2020)
- Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE)
Mae unrhyw newidiadau sydd wedi cael eu gwneud yn barod gan y tîm yn ymddangos yn y cynnwys a chyfeirir atynt gydag anodiadau.Ar ôl y diwrnod ymadael bydd tair fersiwn o’r ddeddfwriaeth yma i’w gwirio at ddibenion gwahanol. Y fersiwn legislation.gov.uk yw’r fersiwn sy’n weithredol yn y Deyrnas Unedig. Y Fersiwn UE sydd ar EUR-lex ar hyn o bryd yw’r fersiwn sy’n weithredol yn yr UE h.y. efallai y bydd arnoch angen y fersiwn hon os byddwch yn gweithredu busnes yn yr UE.
Y fersiwn yn yr archif ar y we yw’r fersiwn swyddogol o’r ddeddfwriaeth fel yr oedd ar y diwrnod ymadael cyn cael ei chyhoeddi ar legislation.gov.uk ac unrhyw newidiadau ac effeithiau a weithredwyd yn y Deyrnas Unedig wedyn. Mae’r archif ar y we hefyd yn cynnwys cyfraith achos a ffurfiau mewn ieithoedd eraill o EUR-Lex.
Point in time view as at 31/12/2020.
There are currently no known outstanding effects for the Council Decision of 16 September 1985 setting up an Advisory Committee on pharmaceutical training (85/434/EEC).
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
THE COUNCIL OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Economic Community,
Having regard to the draft Decision submitted by the Commission(1),
Whereas, in its resolution of 6 June 1974 concerning the mutual recognition of diplomas, certificates and other evidence of formal qualifications(2), the Council declared itself in favour of the establishment of advisory committees;
Whereas, in the context of the mutual recognition of diplomas, certificates and other evidence of formal qualification in pharmacy, it is important to ensure a comparably high standard of training;
Whereas, to contribute to the attainment of this objective, it is desirable to set up an Advisory Committee to advise the Commission,
HAS DECIDED AS FOLLOWS:
An Advisory Committee on Pharmaceutical Training, hereinafter referred to as the ‘Committee’, shall be set up within the Commission.
1.The task of the Committee shall be to help to ensure a comparably high standard of pharmaceutical training in the Community.
2.It shall carry out this task in particular by the following means:
exchange of comprehensive information as to the training methods and the content, level and structure of theoretical and practical courses provided in the Member States,
discussion and consultation with the object of developing a common approach to the standard to be attained in the training of pharmacists and, as appropriate, to the structure and content of such training,
keeping under review the adaptation of pharmaceutical training to developments in pharmaceutical science and teaching methods.
3.The Committee shall communicate to the Commission and the Member States its opinions and recommendations including, where it considers it appropriate, suggestions for amendments to be made to the Articles relating to pharmaceutical training in Council Directives 85/432/EEC(3) and 85/433/EEC(4).
4.The Committee shall also advise the Commission on any other matter which the Commission may refer to it in relation to pharmaceutical training.
1.The Committee shall consist of three experts from each Member State, as follows:
one expert from the practising pharmaceutical profession,
one expert from the pharmaceutical science teaching institutions,
one expert from the competent authorities of the Member States.
2.There shall be an alternate for each member. Alternates may attend the meetings of the Committee.
3.The members and alternates described in paragraphs 1 and 2 shall be nominated by the Member States. The members referred to in the first and second indents of paragraph 1 and their alternates shall be nominated upon the proposal of the practising pharmaceutical profession and the pharmaceutical science teaching institutions. The members and alternates thus nominated shall be appointed by the Council.
1.The term of office for a member of the Committee shall be three years. After the expiry of that period the members of the Committee shall remain in office until replacements have been provided for or until their appointment is renewed.
2.The term of office of a member may end before expiry of the period of three years in the event of the resignation or death of the member, or of his being replaced by another person, in accordance with the procedure laid down in Article 3. The appointment of a new member shall be for the remainder of the term of office.
The Committee shall elect from among its members a chairman and two deputy-chairmen. It shall adopt its own rules of procedure. The agenda for meetings shall be drawn up by the chairman of the Committee in consultation with the Commission.
The Committtee may set up working parties and call upon and allow observers or experts to assist it in connection with all the special aspects of its work.
The secretariat of the Committee shall be provided by the Commission.
Done at Luxembourg, 16 September 1985.
For the Council
The President
M. Fischbach
See page 34 of this Official Journal.
See page 37 of this Official Journal.
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE): Mae'r wreiddiol version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Pwynt Penodol mewn Amser: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
Mae’r llinell amser yma yn dangos y fersiynau gwahanol a gymerwyd o EUR-Lex yn ogystal ag unrhyw fersiynau dilynol a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig.
Cymerir dyddiadau fersiynau’r UE o ddyddiadau’r dogfennau ar EUR-Lex ac efallai na fyddant yn cyfateb â’r adeg pan ddaeth y newidiadau i rym ar gyfer y ddogfen.
Ar gyfer unrhyw fersiynau a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig, bydd y dyddiad yn cyd-fynd â’r dyddiad cynharaf y daeth y newid (e.e. ychwanegiad, diddymiad neu gyfnewidiad) a weithredwyd i rym. Am ragor o wybodaeth gweler ein canllaw i ddeddfwriaeth ddiwygiedig ar Ddeall Deddfwriaeth.
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys